Logan Capital Management Inc. Reduces Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Logan Capital Management Inc. lowered its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 3.1% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 29,030 shares of the medical equipment provider’s stock after selling 925 shares during the period. Logan Capital Management Inc.’s holdings in Lantheus were worth $3,186,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB purchased a new position in Lantheus during the third quarter valued at $25,000. Signaturefd LLC lifted its position in Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 92 shares during the period. Nkcfo LLC bought a new stake in Lantheus during the second quarter worth about $47,000. UMB Bank n.a. boosted its stake in Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after acquiring an additional 126 shares in the last quarter. Finally, Kathleen S. Wright Associates Inc. purchased a new stake in Lantheus in the third quarter worth about $51,000. 99.06% of the stock is owned by institutional investors.

Lantheus Trading Up 1.2 %

Shares of LNTH opened at $93.02 on Friday. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89. The business’s fifty day simple moving average is $97.88 and its two-hundred day simple moving average is $97.85. The company has a market cap of $6.47 billion, a price-to-earnings ratio of 15.48 and a beta of 0.45.

Analyst Upgrades and Downgrades

LNTH has been the subject of several recent research reports. JMP Securities lowered their target price on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a report on Thursday, November 7th. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Truist Financial reissued a “buy” rating and issued a $120.00 target price (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, Redburn Atlantic assumed coverage on Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target for the company. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $130.00.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.